Cypherpunk Technologies Inc. (CYPH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cypherpunk Technologies Inc. (CYPH) has a cash flow conversion efficiency ratio of -0.067x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-16.29 Million) by net assets ($242.22 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cypherpunk Technologies Inc. - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Cypherpunk Technologies Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Cypherpunk Technologies Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cypherpunk Technologies Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Dedicare AB (publ)
ST:DEDI
|
-0.118x |
|
Samhwa Crown
KO:004450
|
0.022x |
|
Level Biotechnology
TWO:3118
|
0.021x |
|
Rotork PLC
LSE:ROR
|
0.070x |
|
LIGHTON
PA:ALTAI
|
-0.386x |
|
JFB Construction Holdings Class A Common Stock
NASDAQ:JFB
|
-0.062x |
|
Candles Scandinavia AB Series B
ST:CANDLE-B
|
0.045x |
|
Tocvan Ventures Corp
F:TV3
|
-0.071x |
Annual Cash Flow Conversion Efficiency for Cypherpunk Technologies Inc. (2012–2024)
The table below shows the annual cash flow conversion efficiency of Cypherpunk Technologies Inc. from 2012 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $35.05 Million | $-60.30 Million | -1.720x | -136.49% |
| 2023-12-31 | $60.14 Million | $-43.75 Million | -0.728x | +18.95% |
| 2022-12-31 | $54.64 Million | $-49.04 Million | -0.898x | -175.43% |
| 2021-12-31 | $107.89 Million | $-35.16 Million | -0.326x | +15.38% |
| 2020-12-31 | $67.41 Million | $-25.96 Million | -0.385x | +91.81% |
| 2019-12-31 | $5.72 Million | $-26.90 Million | -4.701x | -65.67% |
| 2018-12-31 | $9.18 Million | $-26.03 Million | -2.837x | -42.49% |
| 2017-12-31 | $11.12 Million | $-22.14 Million | -1.991x | -- |
| 2016-12-31 | $0.00 | $-25.34 Million | x | -- |
| 2015-12-31 | $26.87 Million | $-19.58 Million | -0.729x | -86.90% |
| 2014-12-31 | $46.21 Million | $-18.02 Million | -0.390x | +26.38% |
| 2013-12-31 | $18.77 Million | $-9.94 Million | -0.530x | +8.14% |
| 2012-12-31 | $13.10 Million | $-7.55 Million | -0.577x | -- |
About Cypherpunk Technologies Inc.
Cypherpunk Technologies Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead clinical stage drug candidate includes DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in various ongoing clinical trials for treating esophagogastric and gynecologic cancers, and colorectal cancer. The company also develops FL-… Read more